Oncology Corporate Profile
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.
2/28/2017 12:01 pm
2/28/2017 12:00 pm
[PR Newswire] - PETACH TIKVA, Israel, Feb. 28, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced new data that show its liver disease drug candidate Namodenoson (CF102) prevented liver (hepatic) fibrosis progression in preclinical studies. "These latest study results add to the growing body of data that demonstrate Namodenoson's potential efficacy in combating non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH), indications for which there is currently no FDA approved drug. Liver fibrosis is the excessive accumulation of scar tissue resulting from ongoing inflammation.
2/23/2017 04:00 pm
2/8/2017 12:00 pm
[PR Newswire] - PETACH TIKVA, Israel, Feb. 8, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today the Company is ready to commence patient enrollment in the second quarter of 2017 in its global Phase III trial of its lead drug candidate Piclidenoson as a first line treatment for rheumatoid arthritis. The required supply of Piclidenoson has already been manufactured and paid. Piclidenoson is being developed as a first line therapy and replacement for the current standard of care, Methotrexate (MTX), the most widely used drug for rheumatoid arthritis.
1/19/2017 12:02 pm
[PR Newswire] - PETACH TIKVA, Israel, Jan. 19, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has entered into definitive agreements with institutional investors to receive gross proceeds of $5 million. In connection with the offering, the Company will issue 2,500,000 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $2.00 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase 50% of an ADS. The warrants have an exercise price of $2.25 per ADS, shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. The closing of the offering is expected to take place on or about January 24, 2017, subject to the satisfaction of customary closing conditions.
1/9/2017 12:00 pm
[PR Newswire] - Approximately 60 patients with NAFLD, with or without NASH, will be enrolled in three arms, including two different dosages of Namodenoson and a placebo, given via oral tablets twice daily. Secondary endpoints to be evaluated are the effects of Namodenoson on metabolic abnormalities in subjects with NAFLD, including body weight, waist circumference, serum triglyceride and high-density lipoprotein cholesterol levels, and serum liver transaminase.
12/21/2016 12:00 pm
[PR Newswire] - Can-Fite recently announced entering a distribution agreement with CKD for the exclusive right to distribute Namodenoson (CF102) for the treatment of liver cancer in South Korea, upon receipt of regulatory approvals, for up to $3,000,000 in upfront and milestone payments, plus royalties on net sales of 23%. "We are pleased to receive this upfront payment of $500,000 from CKD and look towards future potential milestone payments as we advance Namodenoson through completion of our current Phase II trial as a second line treatment for hepatocellular carcinoma and into Phase III," stated Can-Fite CEO Dr. Pnina Fishman. Per the terms of the distribution agreement, Can-Fite will deliver finished product to CKD and CKD has a right of first refusal to distribute Namodenoson for other indications for which Can-Fite develops Namodenoson.
12/16/2016 12:00 pm
[PR Newswire] - This outcome suggests the anti-fibrotic effect of the drug and supports its development as an agent to combat non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH). Pre-clinical studies which evaluated the effects of Namodenoson on fibrogenic hepatic stellate cells were conducted under the supervision of Prof. Rifaat Safadi M.D., a Key Opinion Leader in the field of liver diseases, and Director of Liver Unit, Institute of Gastroenterology and Liver Diseases, Hadassah University Hospital, Ein Kerem.
11/25/2016 12:00 pm
[PR Newswire] - PETACH TIKVA, Israel, Nov. 25, 2016 /PRNewswire/ -- Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to ...
11/16/2016 12:00 pm
[PR Newswire] - "Assignment of a unique generic name is a very meaningful move forward for our liver cancer and NASH drug candidate, CF102. With both Fast Track and Orphan Drug status in the U.S. as a second line treatment for hepatocellular carcinoma, the Company is conducting a global Phase II liver cancer study.
11/9/2016 12:00 pm
[PR Newswire] - This marks Can-Fite's second notice of allowance in the U.S. for ligands which bind to the A3AR target. Can-Fite's CF602, an allosteric compound at the A3AR demonstrated effects on erection superior to that demonstrated by sildenafil (Viagra®) in diabetic animal studies.
11/7/2016 12:00 pm
[PR Newswire] - BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. Dr. Fishman is scheduled to meet with numerous decision makers at biotech and pharmaceutical companies interested in Can-Fite's pipeline of drug candidates including its lead candidate Piclidenoson (CF101) for autoimmune disease, CF102 for liver cancer and NASH, and CF602 for sexual dysfunction.
11/1/2016 11:00 am
[PR Newswire] - Can-Fite intends to initiate the Phase III trial in the second half of 2017. The planned Phase III trial is a randomized, double-blind, placebo- and active-controlled study that will investigate the efficacy and safety of daily Piclidenoson administered orally as compared to placebo as its primary endpoint and as compared to apremilast (Otezla®) as its secondary endpoint in approximately 400 patients with moderate-to-severe plaque psoriasis.
10/25/2016 11:01 am
[PR Newswire] - The distribution agreement further provides that Can-Fite will deliver finished product to CKD and grants CKD a right of first refusal to distribute CF102 for other indications for which Can-Fite develops CF102. "This agreement marks our first distribution deal for CF102 as we near completion of patient enrollment in our Phase II trial of CF102 as a second line treatment for hepatocellular carcinoma.
10/14/2016 04:03 pm
10/13/2016 11:00 am
[PR Newswire] - Based on the protocol that was submitted, Can-Fite's Phase II study, designed by world renowned Key Opinion Leaders in the field of liver diseases, will be a multicenter, randomized, double-blinded, placebo-controlled, dose-finding study of the efficacy and safety of CF102 in the treatment of NAFLD/NASH. The study will enroll approximately 60 patients with NAFLD, with or without NASH, and will have three arms, including two different dosages of CF102 and a placebo, given via oral tablets twice daily.
9/21/2016 12:02 am
9/20/2016 11:00 am
[PR Newswire] - PETACH TIKVA, Israel, Sept. 20, 2016 /PRNewswire/ -- Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed ...
9/15/2016 03:00 pm
9/13/2016 11:00 am
[PR Newswire] - Piclidenoson will be evaluated in an upcoming Phase III trial in Europe in which it will be compared to apremilast (Otezla®), a recently approved oral drug from Celgene. Can-Fite submitted its Phase III clinical trial protocol for Piclidenoson in the treatment of moderate-to-severe psoriasis to the European Medicines Agency (EMA) in the first half of 2016.
9/7/2016 11:00 am
[PR Newswire] - The Rodman & Renshaw conference, sponsored by H.C. Wainright & Co., takes place from September 11-13, 2016 in New York City. Dr. Fishman and Mr. Farbstein will be conducting one-on-one meetings during the conference.
8/26/2016 11:00 am
[PR Newswire] - PETACH TIKVA, Israel, Aug. 26, 2016 /PRNewswire/ -- Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to ...
8/24/2016 05:04 pm
8/8/2016 11:00 am
[PR Newswire] - The study titled, "Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial," was published in the August 2016 issue of the journal. The published study provides details regarding patient population, safety profile, and Piclidenoson's efficacy as compared to apremilast, a drug approved by the U.S. Food and Drug Administration to treat moderate to severe psoriasis and is marketed under the brand name Otezla® by Celgene.
7/25/2016 11:00 am
[PR Newswire] - NAFLD is characterized by excess fat accumulation in the form of triglycerides (steatosis) in the liver. According to a recent study published in Hepatology, an estimated 25% of the population in the U.S. has NAFLD, with a higher prevalence in people with type II diabetes. NAFLD includes a range of liver diseases, with NASH being the more advanced form, manifesting as hepatic injury and inflammation.